Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

This study is ongoing, but not recruiting participants.
Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Drug/Agent Toxicity by Tissue/Organ
			Pancreatic Cancer
2		Additional conditions recognized in this trial
			Pancreatic Neoplasms
3		More general conditions related to this trial
			Digestive System Diseases
			Digestive System Neoplasms
			Endocrine Gland Neoplasms
			Endocrine System Diseases
			Neoplasms
			Neoplasms by Site
			Pancreatic Diseases
4		Interventions listed in this trial
			fluorouracil
			gemcitabine hydrochloride
			triacetyluridine
5		Additional drug interventions recognized in this trial
			Gemcitabine
6		More general drug interventions related to this trial
			Anti-Infective Agents
			Antimetabolites
			Antimetabolites, Antineoplastic
			Antineoplastic Agents
			Antiviral Agents
			Enzyme Inhibitors
			Immunologic Factors
			Immunosuppressive Agents
			Molecular Mechanisms of Pharmacological Action
			Pharmacologic Actions
			Physiological Effects of Drugs
			Radiation-Sensitizing Agents
			Therapeutic Uses
7		Sponsors listed in this trial
			Wellstat Therapeutics